Skip to main content
. Author manuscript; available in PMC: 2020 Apr 7.
Published in final edited form as: Oncogene. 2019 Oct 7;39(5):1031–1040. doi: 10.1038/s41388-019-1034-9

Figure 5. RBM10 interacts with MDM2.

Figure 5.

(A and B) Exogenous RBM10 interacts with p53. HCT116p53−/− cells were transfected with plasmids encoding RBM10 and Flag-MDM2 or HA-MDM2 and Flag-RBM10 as indicated followed by co-IP-IB assays using antibodies as indicated. (C) The association between endogenous RBM10 and p53 is detected in HCT116p53+/+ cells by co-IP-IB assays using antibodies as indicated. IgG was used as a control. (D) Mapping the RBM10 binding domain of MDM2 by GST-pull down assay. HCT116p53−/− cells were transfected with Flag-RBM10 encoded plasmid, and the cell lysate was incubated with GST-tagged full-length MDM2 or MDM2 fragment, aa 1-150, aa 1-301 or aa 294-491, or GST protein alone. Bound proteins were detected by IB with the anti-RBM10 antibody or using coomassie staining. (E) Exogenous RBM10 inhibits p53-MDM2 binding. HCT116p53−/− cells were transfected with combinations of plasmids encoding p53, HA-MDM2 or RBM10 as indicated followed by co-IP-IB assays using antibodies as indicated.